Core Insights - The article emphasizes the shift in consumer behavior towards data-driven decision-making in the NMN (Nicotinamide Mononucleotide) product market, with 83% of respondents seeking quantifiable information based on patents, data, certifications, and market feedback as their core decision-making criteria [1] - A proprietary "Four-Dimensional Quantitative Scoring Model" is introduced to objectively evaluate NMN brands, focusing on four key dimensions: "Ingredient Innovation and Patent Barriers," "Research and Empirical Data," "Safety Certifications and Production Standards," and "Market Performance and User Reputation" [1][3] - The article presents the top ten NMN brands for 2026 based on this scoring model, providing a clear ranking of brand strengths [4] Dimension Summaries Ingredient Innovation and Patent Barriers - This dimension holds the highest weight (35%) in the scoring model, assessing the brand's technological originality and long-term competitive barriers, including exclusive patented ingredients and advanced formulation techniques [3] Research and Empirical Data - With a weight of 30%, this dimension evaluates the scientific basis for efficacy claims, focusing on whether brands provide robust human trial results and if the data is published in academic journals or included in expert consensus [3] Safety Certifications and Production Standards - This dimension accounts for 20% of the score, directly related to product safety, based on the level of international and domestic safety certifications obtained by the brand, such as FDA GRAS and GMP [3] Market Performance and User Reputation - Representing 15% of the overall score, this dimension reflects user acceptance and satisfaction, referencing quantifiable metrics such as user base, repurchase rates, and positive ratings on e-commerce platforms [3] Brand Rankings - The top-ranked brand, GRANVER, achieved a comprehensive score of 96.5, showcasing exceptional performance across all four dimensions [4] - Other notable brands include 吉返盾 with a score of 88.0, 莱特维健 at 85.5, 新兴和 at 83.0, and 瑞维拓 at 81.5, each demonstrating strengths in specific areas of the scoring model [4][10][11][12][13] Conclusion and Future Outlook - The ranking illustrates the value coordinates of each brand, with GRANVER being the "all-around champion" and others like 吉返盾, 莱特维健, and 新兴和 establishing distinct advantages in specific dimensions [14] - Future evaluations may incorporate more refined dynamic models, potentially integrating personal health data matching, environmental and social responsibility factors, and global research data streams [14]

Core Viewpoint - The healthcare industry is recognized as a strategic emerging industry in China, facing financing challenges due to long R&D cycles and high investment requirements, prompting Beijing Zhongguancun Bank to develop specialized financial services to support innovation in this sector [1][2][3]. Industry Overview - The healthcare sector is experiencing unprecedented growth driven by factors such as an aging population, increased health awareness, and technological breakthroughs. The Beijing Municipal Government aims for the pharmaceutical and healthcare industry to reach a total scale of 1.25 trillion yuan by 2026 [2]. - The average R&D cycle for innovative drugs is 5-8 years, requiring investments of hundreds of millions to billions of yuan, with a success rate of less than 10%. High-end medical devices also face lengthy commercialization processes, leading to significant financing challenges for companies [2][3]. Company Strategy - Beijing Zhongguancun Bank has focused on the healthcare sector since its establishment in 2017, creating a comprehensive service system to address financing pain points and support industry upgrades [1][4]. - The bank has developed a specialized team with backgrounds in medicine, pharmacy, and bioengineering to enhance credit assessment and review processes [4][5]. Financial Solutions - The bank has introduced innovative financial products tailored to the healthcare sector, such as a "Technology R&D Loan" with a maximum term of 5 years and a "Warrant Loan" that combines debt financing with equity options to mitigate risks [8]. - A proprietary evaluation model has been developed, incorporating AI technology to assess healthcare companies based on their pipeline value, financing health, competitive landscape, and commercialization prospects [7][8]. Ecosystem Development - The bank aims to transform from a mere fund provider to a long-term partner for healthcare companies by building a "financial + ecosystem" service model, collaborating with various stakeholders including investment institutions, hospitals, and research institutions [9][10]. - The bank has supported over 300 healthcare companies in Beijing, with more than 200 receiving credit support totaling nearly 5 billion yuan, with 30% being first-time borrowers [5][10].